UK availability of Rixathon and Erelzi paves way for NHS savings
Two new biosimilar medicines available to treat patients with specific blood cancers and a range of inflammatory condition.
Sandoz, a Novartis division, has announced the UK availability of two new biosimilar medicines for use in Europe, Rixathon (biosimilar rituximab) and Erelzi (biosimilar etanercept) to treat patients with specific blood cancers and a range of inflammatory conditions. The availability has the potential to increase access to these medicines for eligible patients in the UK, in line with the indications of the reference medicines MabThera and Enbrel.
Dr Samir Agrawal, Consultant Haematologist at St Bartholomew’s Hospitals and The Barts Health NHS Trust, said, “The availability of new biosimilar medicines – which offer equal efficacy to the originator products and provide both patients and physicians more choice in treatment options – offer a real opportunity for cost savings within the NHS, that may then be reinvested back into the health service. This comes at a crucial time for the NHS, which is currently constrained by enormous financial pressure. The hope is that rapid uptake of the medicines will translate to cost savings for the NHS which patients may quickly benefit from.”
The NHS spent £16.8 billion on medicines in 2015/16, an increase of 8 percent from the previous year.[ii] Last year, the NHS spent over £415 million on rituximab and etanercept. The introduction of cost-effective biosimilar rituximab and biosimilar etanercept may provide much needed cost savings for the NHS, freeing up resources to improve patient access to existing medicines and contributing to its financial sustainability.
Rixathon will be available for patients with non-Hodgkin’s lymphoma (NHL) – follicular lymphoma and diffuse large B-cell lymphoma – and chronic lymphocytic leukaemia, as well as immunological diseases such as rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. Collectively, these diseases affect approximately 416,500 people in the UK.
Additionally, Erelzi will be available for various patients with inflammatory conditions, including rheumatoid arthritis, axial spondyloarthritis – ankylosing spondylitis and non-radiographic axial spondyloarthritis – plaque psoriasis, psoriatic arthritis, juvenile idiopathic arthritis and paediatric plaque psoriasis. In the UK over 2.4 million people are affected by these diseases each year.
Commenting on the news, Tim de Gavre, Country Head of Sandoz UK, said: “The availability of Rixathon and Erelzi marks an important milestone for the NHS, for patients and for Sandoz. Biosimilar medicines such as these have real potential to expand patient access to effective treatments, while providing the NHS with essential cost savings. Today’s availability of not just one, but two, new Sandoz biosimilar medicines makes us the only company to have five approved biosimilar medicines in Europe, cementing our leadership in this space and reinforcing our commitment to providing these much-needed medicines to patients.”
Approval and subsequent availability of these medicines was based on analytical, pre-clinical, and clinical data demonstrating biosimilarity to the respective reference medicines. Clinical studies of biosimilar rituximab included a PK/PD trial in rheumatoid arthritis (ASSIST-RA), and a Phase III confirmatory safety and efficacy study in follicular lymphoma (ASSIST-FL). Clinical studies of biosimilar etanercept included data from an innovative Phase III confirmatory safety and efficacy study in moderate to severe plaque psoriasis (EGALITY).
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance